With claims of potential Alzheimer’s edge, Vaxxinity squeaks out $88M IPO


Vaxxinity, a clinical-stage biotech with vaccine technology that gets the body to produce therapeutic or protective antibodies, raised $88 million from an IPO that priced below the targeted price range. In addition to its lead Alzheimer’s disease program, Vaxxinity’s pipeline includes product candidates for Parkinson’s disease, migraine, and Covid-19.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.